Nacho De Marco

The premier national members-only network for Latino and Hispanic leaders, and the best leadership investment for diversity-friendly employers. We provide: Premier networking events and meeting spaces in leading US cities like SF, NYC, LA, Chicago, Miami, Atlanta, Dallas, and Austin. In-person and virtual coaching and workshops with outstanding Latino and Hispanic leaders and peers, which offer a unique experience to learn, grow, engage, and simply do more with less. Remote and in-person, invitation-only keynote speeches with Latino and Hispanic leaders of Fortune 500-level companies like Honeywell and Pfizer, and best-in-class tech leaders like, Google, DoorDash, Uber and BairesDev. Exclusive access to board seat opportunities to advance diversity in corporate governance. Recruitment of high performing LatinX leaders, and programs for world-class employee retention.

COR is the all-in-one management solution for professional services that automate timesheets, through AI, to predict profitability, reduce work overload and improve client engagements.

We are developing an entirely novel class of orally available small molecules to address untreatable cancers. Our first drug, Ag5, aims to redefine the treatment landscape for solid tumours on both sides of the blood brain barrier by targeting the 30% of all cancers that generate high levels of Reactive Oxygen Species. This large group contains cancers driven by mutations in the KRAS gene, triple negative breast cancer and glioblastoma-all of which are urgent unmet medical needs with large potential markets. We have a deep pipeline of follow on medicines. Our goal is to revolutionise cancer treatment for patients and their doctors.

We are the leading pharmacy purchasing platform that drives efficiency, transparency and growth in the pharmaceutical industry. With Extendeal, pharmacies can connect with multiple wholesalers, find the best prices and deals, and execute their purchases efficiently. Join the pharma purchasing revolution 🚀

Healthier Friends is a non-profit organization dedicated to compiling and assessing all research on anti-age treatment, fostering peer review among the scientific community, and leveraging modern AI tools. The ultimate goal is to produce scientific evidence-based recommendations and allow individuals to track the progress of their therapies of choice. Healthier Friends will help promising research groups through access to technology and investment.

The premier national members-only network for Latino and Hispanic leaders, and the best leadership investment for diversity-friendly employers. We provide: Premier networking events and meeting spaces in leading US cities like SF, NYC, LA, Chicago, Miami, Atlanta, Dallas, and Austin. In-person and virtual coaching and workshops with outstanding Latino and Hispanic leaders and peers, which offer a unique experience to learn, grow, engage, and simply do more with less. Remote and in-person, invitation-only keynote speeches with Latino and Hispanic leaders of Fortune 500-level companies like Honeywell and Pfizer, and best-in-class tech leaders like, Google, DoorDash, Uber and BairesDev. Exclusive access to board seat opportunities to advance diversity in corporate governance. Recruitment of high performing LatinX leaders, and programs for world-class employee retention.

COR is the all-in-one management solution for professional services that automate timesheets, through AI, to predict profitability, reduce work overload and improve client engagements.

BDev Ventures is a Venture Capital Fund. We invest in fast-growing post-revenue B2B software companies, from Seed to Series B, as a minority investor with checks up to 3M USD. We are focused on startups operating in the US and LATAM. In addition to capital, we provide our portfolio companies with a proprietary lead generation platform that our founders built and refined. It helped bootstrap BairesDev to unicorn status. Because of the value we can add in reaching new customers, we work with startups that are ready to utilize that platform to the fullest.

We are developing an entirely novel class of orally available small molecules to address untreatable cancers. Our first drug, Ag5, aims to redefine the treatment landscape for solid tumours on both sides of the blood brain barrier by targeting the 30% of all cancers that generate high levels of Reactive Oxygen Species. This large group contains cancers driven by mutations in the KRAS gene, triple negative breast cancer and glioblastoma-all of which are urgent unmet medical needs with large potential markets. We have a deep pipeline of follow on medicines. Our goal is to revolutionise cancer treatment for patients and their doctors.